We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The role of therapy in the outcome of patients with myelofibrosis.
- Authors
Masarova, Lucia; Bose, Prithviraj; Pemmaraju, Naveen; Daver, Naval G.; Sasaki, Koji; Chifotides, Helen T.; Zhou, Lingsha; Kantarjian, Hagop M.; Estrov, Zeev; Verstovsek, Srdan
- Abstract
BACKGROUND: The treatment of patients with myelofibrosis (MF) has evolved in the past decade, as reflected in an increased use of various therapeutic agents that could potentially impact patient outcomes. METHODS: In this retrospective study, the authors evaluated the pattern of therapy and its possible impact on the survival of patients with MF at their institution. Patients (n = 802) with newly diagnosed, chronic, overt MF (MF fibrosis grade ≥2, <10% blasts) seen at their cancer center between 2000 and 2020 were included. RESULTS: Overall, 492 of the included patients (61%) initiated MF‐directed therapy during follow‐up. The most frequent initial therapy was the JAK inhibitor ruxolitinib (44% of treated patients), investigational agents excluding JAK inhibitors (21%), immunomodulatory agents (18%), other investigational JAK inhibitors (10%), and others (7%). Overall survival was superior for patients who received initial ruxolitinib therapy, with a median survival of 72 months versus approximately 50 months for the remaining approaches, excluding the last group. Thirty‐two percent of patients required subsequent therapy (n = 159). The longest survival since the start of second‐line therapy was observed in patients who initiated salvage ruxolitinib (median, 35 months; 95% CI, 25–45 months). CONCLUSIONS: This study demonstrated improved outcomes of patients with MF who received treatment with the JAK inhibitor ruxolitinib. This single‐center study suggests that ruxolitinib played a central role in improved survival among patients with myelofibrosis. Patients who are not eligible for ruxolitinib require novel therapies.
- Subjects
MYELOFIBROSIS; RUXOLITINIB; OVERALL survival; SURVIVAL rate
- Publication
Cancer (0008543X), 2023, Vol 129, Issue 18, p2828
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.34851